Genenta Science (GNTA) Competitors $3.42 -0.05 (-1.30%) As of 01:39 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GNTA vs. MREO, SCPH, IMMP, DMAC, TKNO, ZYBT, ALMS, NMRA, PBYI, and GALTShould you be buying Genenta Science stock or one of its competitors? The main competitors of Genenta Science include Mereo BioPharma Group (MREO), scPharmaceuticals (SCPH), Prima BioMed (IMMP), DiaMedica Therapeutics (DMAC), Alpha Teknova (TKNO), Zhengye Biotechnology (ZYBT), Alumis (ALMS), Neumora Therapeutics (NMRA), Puma Biotechnology (PBYI), and Galectin Therapeutics (GALT). These companies are all part of the "pharmaceutical products" industry. Genenta Science vs. Its Competitors Mereo BioPharma Group scPharmaceuticals Prima BioMed DiaMedica Therapeutics Alpha Teknova Zhengye Biotechnology Alumis Neumora Therapeutics Puma Biotechnology Galectin Therapeutics Mereo BioPharma Group (NASDAQ:MREO) and Genenta Science (NASDAQ:GNTA) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability. Which has more volatility and risk, MREO or GNTA? Mereo BioPharma Group has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Genenta Science has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Does the media refer more to MREO or GNTA? In the previous week, Mereo BioPharma Group had 16 more articles in the media than Genenta Science. MarketBeat recorded 17 mentions for Mereo BioPharma Group and 1 mentions for Genenta Science. Genenta Science's average media sentiment score of 1.88 beat Mereo BioPharma Group's score of 0.57 indicating that Genenta Science is being referred to more favorably in the news media. Company Overall Sentiment Mereo BioPharma Group Positive Genenta Science Very Positive Do analysts rate MREO or GNTA? Mereo BioPharma Group currently has a consensus price target of $7.20, suggesting a potential upside of 317.39%. Genenta Science has a consensus price target of $25.00, suggesting a potential upside of 632.06%. Given Genenta Science's higher probable upside, analysts clearly believe Genenta Science is more favorable than Mereo BioPharma Group.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mereo BioPharma Group 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Genenta Science 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in MREO or GNTA? 62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 15.1% of Genenta Science shares are held by institutional investors. 5.5% of Mereo BioPharma Group shares are held by company insiders. Comparatively, 29.0% of Genenta Science shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is MREO or GNTA more profitable? Genenta Science's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.Company Net Margins Return on Equity Return on Assets Mereo BioPharma GroupN/A -80.00% -66.94% Genenta Science N/A N/A N/A Which has stronger earnings and valuation, MREO or GNTA? Genenta Science has lower revenue, but higher earnings than Mereo BioPharma Group. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMereo BioPharma Group$10M27.43-$43.25M-$0.07-24.64Genenta ScienceN/AN/A-$9.64MN/AN/A SummaryGenenta Science beats Mereo BioPharma Group on 7 of the 13 factors compared between the two stocks. Get Genenta Science News Delivered to You Automatically Sign up to receive the latest news and ratings for GNTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GNTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNTA vs. The Competition Export to ExcelMetricGenenta ScienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$62.46M$3.14B$5.70B$9.81BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.7530.6225.55Price / SalesN/A367.71465.58116.50Price / CashN/A43.0338.2159.48Price / Book4.618.659.026.15Net Income-$9.64M-$54.65M$3.25B$264.98M7 Day Performance-8.81%6.66%4.83%2.81%1 Month Performance-10.25%9.59%6.81%3.20%1 Year Performance-21.49%14.32%30.56%25.33% Genenta Science Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNTAGenenta Science2.8091 of 5 stars$3.42-1.3%$25.00+632.1%-23.8%$62.46MN/A0.007Positive NewsGap UpMREOMereo BioPharma Group2.0632 of 5 stars$1.62+6.3%$7.20+345.8%-56.7%$256.79M$10M-23.0740News CoverageEarnings ReportAnalyst RevisionSCPHscPharmaceuticals4.4726 of 5 stars$4.83+3.6%$14.00+189.9%+3.3%$255.31M$36.33M-2.6530News CoverageShort Interest ↓IMMPPrima BioMed1.4775 of 5 stars$1.74+2.1%$7.00+303.5%-20.4%$254.68M$5.14M0.002,021DMACDiaMedica Therapeutics1.7779 of 5 stars$4.91+7.1%$10.75+119.1%+72.7%$254.57MN/A-7.7020News CoverageEarnings ReportAnalyst ForecastShort Interest ↑TKNOAlpha Teknova2.4466 of 5 stars$4.63+5.0%$10.00+116.0%+29.4%$247.69M$37.74M-11.04240ZYBTZhengye BiotechnologyN/A$5.21-3.2%N/AN/A$245.76M$25.53M0.00278Positive NewsGap DownALMSAlumis2.8756 of 5 stars$4.49+3.3%$19.80+341.5%-65.5%$244.03MN/A0.00N/ANews CoverageEarnings ReportAnalyst ForecastNMRANeumora Therapeutics2.9205 of 5 stars$1.51+4.5%$7.14+374.6%-85.9%$243.74MN/A-0.96108PBYIPuma Biotechnology4.1467 of 5 stars$4.84-0.3%$7.00+44.8%+95.9%$243.54M$230.50M4.93200GALTGalectin Therapeutics2.0599 of 5 stars$3.79-2.3%$6.00+58.2%+80.8%$242.40MN/A-5.329News CoverageEarnings ReportAnalyst Forecast Related Companies and Tools Related Companies Mereo BioPharma Group Competitors scPharmaceuticals Competitors Prima BioMed Competitors DiaMedica Therapeutics Competitors Alpha Teknova Competitors Zhengye Biotechnology Competitors Alumis Competitors Neumora Therapeutics Competitors Puma Biotechnology Competitors Galectin Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNTA) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genenta Science S.p.A. Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genenta Science With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access